What are the funding trends in AI drug discovery today?

All funding deals in the AI in drug discovery market over the last years

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report covering the AI In Drug Discovery Market.

Is AI drug discovery funding really booming right now?

AI drug discovery funding is much stronger today, but the boom is concentrated in the amount of money being invested rather than in the number of startups raising.

We tracked 38 financings so far in 2026, compared with 37 over the same period in 2025 and 31 in 2024. Reliable capital, however, jumped to $3.35 billion from $1.50 billion last year and $826.9 million two years ago.

Deal activity barely changed year on year, while the amount invested more than doubled.

The typical financing did get somewhat larger. The median reliable round rose from $10 million to $12.29 million. But the average shot from $40.4 million to $90.5 million, which is what happens when a handful of enormous transactions pull the market upward.

There is some genuine expansion compared with 2024. Seven more deals were completed and five more companies raised money. Still, those increases are modest beside the roughly fourfold rise in capital.

Today, AI drug discovery has far more money flowing into it, without anything close to the same increase in the number of companies benefiting.

Metric	2026 YTD	2025 same period	2024 same period
Deals	38	37	31
Unique companies	36	35	31
Reliable capital	$3.35B	$1.50B	$826.9M
Median round	$12.29M	$10.0M	$25.0M
Average round	$90.5M	$40.4M	$28.5M
First-financing share	23.7%	32.4%	29.0%
Follow-on share	76.3%	67.6%	71.0%
Later-stage share	27.3%	17.6%	21.4%

Is Isomorphic Labs basically carrying the AI drug discovery funding boom?

Isomorphic Labs is doing an extraordinary amount of the work behind the 2026 AI drug discovery funding headline.

The company raised a $2.1 billion Series B this year, equal to roughly 63% of all reliable capital we counted. A single transaction therefore represents almost two-thirds of the market total.

The comparison with last year is just as striking. Isomorphic had already raised $600 million in 2025, meaning the largest round in both periods came from the same company. Its latest financing was 3.5 times larger.

Chai Discovery then added a $400 million Series C, while Syneron Bio raised $150 million in Series B funding. Once rounds of that size enter a market with fewer than 40 transactions, the headline total can move very quickly even if ordinary fundraising conditions barely change.

The concentration reaches well beyond the largest deal. The top three financings account for 79.1% of current capital, up from 57.5% last year and 30.8% in 2024. The top five now account for 84.5%.

So yes, Isomorphic heavily distorts the headline, although several other very large rounds are pushing in the same direction.

Does the AI drug discovery boom survive if we remove the giant rounds?

Barely. Once the biggest AI drug discovery rounds are stripped out, 2026 still looks better than 2025, but only moderately.

When we exclude financings above $100 million, current funding falls to $699.6 million. That is just 9.9% higher than the $636.6 million recorded over the same period last year.

The two-year comparison is even more revealing. The equivalent figure in 2024 was $706.9 million, which means funding below the $100 million threshold is currently about 1% lower than two years ago.

A tighter $50 million cutoff produces a somewhat stronger year-on-year result. Current funding becomes $459.6 million, up 17% from 2025. Yet that figure remains below 2024.

There are still signs that ordinary rounds have improved lately. Financings below $5 million have become much less common, while more deals sit in the $5 million-to-$50 million range. The median round is also higher than last year.

Normal fundraising has improved somewhat. Megarounds explain most of the spectacular headline growth. A market that leans on a few megarounds carries risks we rate by likelihood, less obvious ones included, in our report on AI drug discovery.

Funding test	2026	2025	2024	2026 vs. 2025
Total reliable capital	$3.350B	$1.497B	$826.9M	+123.8%
Excluding >$50M rounds	$459.6M	$392.8M	$571.9M	+17.0%
Excluding >$100M rounds	$699.6M	$636.6M	$706.9M	+9.9%
Median reliable round	$12.29M	$10.0M	$25.0M	+22.9%
Top-1 capital share	62.7%	40.1%	14.5%	+22.6 pp
Top-3 capital share	79.1%	57.5%	30.8%	+21.6 pp
Top-5 capital share	84.5%	69.1%	42.9%	+15.4 pp
$100M+ rounds	4	3	1	+1

Are more AI drug discovery startups getting funded, or are investors just backing the winners harder?

AI drug discovery investors are mainly putting more money behind companies that have already raised before, rather than funding a much larger crop of new startups.

Only one more unique company has raised this year than over the same period in 2025. More tellingly, first financings fell from 12 to nine, while follow-on rounds increased from 25 to 29.

The money is even more concentrated than the deal count. We calculate about $155.8 million of reliable capital going into first financings compared with roughly $3.19 billion going into follow-ons.

New companies can still raise. Boltz launched with a $28 million seed round, Topos Bio secured $10.5 million and 10x Science raised $4.8 million. Seed deal count overall has actually held up well.

But those companies are entering a market where the really large pools of capital are going to businesses that have already passed through earlier fundraising rounds.

Aureka shows how fast this progression can happen. The company, founded in 2023, raised $35 million in an earlier round this year and then closed a $100 million Series B. Chai, founded in 2024, has already reached a $400 million Series C.

Because private financing histories are not always fully public, we treat the exact first-financing split as directional rather than perfect. Even with that caveat, the pattern is clear: investors are currently spending much more on scaling winners than on expanding the number of new entrants.

Are early-stage AI drug discovery startups having a harder time raising?

Early-stage AI drug discovery is still active, but the biggest money has moved further down the funding cycle.

Seed activity itself is holding up. We counted 16 seed rounds this year, against 15 last year and 13 in 2024. Roughly 42% of current deals are still seeds.

The break appears mainly after that. Series A fell from 13 deals last year to eight now, while Series B jumped from one to seven.

Among financings with a known stage, the early-stage share dropped from 82.4% to 72.7%. Later-stage deals moved in the opposite direction, reaching 27.3%.

Investors are still willing to finance new technology and new teams, but much larger checks are going to companies that can already show more than a promising model.

Isomorphic, Syneron, Aureka, Superluminal Medicines and Turbine all raised Series B capital this year. Their stories differ, but each company can point to a developed platform, pipeline work, pharmaceutical relationships or a route toward clinical use.

Founders at the beginning of the funding cycle therefore still have a market. The huge increase in capital is simply happening several stages ahead of them. What would carry this capital surge down to earlier stages is among the growth drivers we weigh in our report on AI drug discovery.

Why are Series B rounds suddenly so big in AI drug discovery?

Series B has become unusually important in AI drug discovery because a group of young AI-native biotechs has reached the expensive part of turning computational platforms into actual drug-development businesses.

Isomorphic's $2.1 billion Series B is the extreme example. The company says the funding will be used to scale its AI drug-design engine, expand globally and move therapeutic programs toward the clinic.

Syneron Bio's $150 million Series B tells a similar story at a smaller scale. The company plans to keep developing its AI-driven macrocyclic peptide platform while pushing more programs into clinical development.

Superluminal Medicines raised $60 million to advance its lead program toward the clinic. Turbine's $25 million Series B is funding an expansion of its virtual-biology platform and additional proprietary experimental data.

Once companies reach this point, the cost profile changes. They need experimental infrastructure, larger research teams, proprietary datasets, pipeline development and, eventually, clinical work. That requires far more capital than building an initial model or software product.

Several companies founded only a few years ago are already moving from model-building into capital-intensive drug development. That is the part of the Series B wave worth watching.

Why is De Novo Design getting so much AI drug discovery funding?

De Novo Design has become the center of gravity for AI drug discovery capital because investors are writing much bigger checks to companies trying to design molecules directly with AI.

The category represents 47.4% of current deals, almost unchanged from 45.9% last year and 45.2% in 2024. So there has been no sudden explosion in the number of De Novo financings.

What changed is the money. The category's share of reliable capital climbed from 47.1% in 2024 to 72.2% last year and 87.7% today.

Isomorphic accounts for much of that jump, but Chai's $400 million Series C, Aureka's $100 million Series B and a long tail of smaller financings make the pattern broader than one company.

There is also more commercial evidence around some of these platforms now. Chai currently highlights collaborations or agreements involving Pfizer, Novartis, Lilly, argenx and Bristol Myers Squibb. Boltz launched with a Pfizer partnership and later announced a collaboration with GSK. Isomorphic is advancing both partnered and internal programs.

Investors are seeing more opportunities to connect AI-designed molecules with actual pharma workflows. That helps explain why the category can attract progressively larger checks even though its share of total deals has barely moved.

Category	Current deals	Deal share	Reliable capital	Capital share
De Novo Design	18	47.4%	$2.94B	87.7%
AI Lead Generation	7	18.4%	$221M	6.6%
AI Drug Repurposing	2	5.3%	$67M	2.0%
Preclinical Prediction AI	5	13.2%	$64.8M	1.9%
AI Target Discovery	5	13.2%	$47M	1.4%
AI Lead Optimization	1	2.6%	$12.3M	0.4%
Total	38	100%	$3.35B	100%

Is AI Lead Generation quietly becoming more popular with investors?

AI Lead Generation is one of the few parts of AI drug discovery where we currently see a clear increase in deal activity without a corresponding explosion in capital.

Seven companies in the category raised during the current period, versus four last year. Its share of deals has increased from 10.8% to 18.4%.

The category's share of capital actually fell, from 11.2% to 6.6%. Investors are doing more Lead Generation deals, but the typical pattern is much less extreme than in De Novo Design.

Syneron Bio is the obvious exception with its $150 million Series B. Around it, deal sizes are much more modest: AIPher raised about $14.9 million, 20n Bio $7.5 million and Stoked Bio $2.5 million.

That mix is useful because the increased activity is spread across several companies rather than being created entirely by one megaround.

These days, Lead Generation looks like an area where investor attention is widening, even if the largest pools of money remain elsewhere. What counts as AI lead generation, and what doesn't, is defined in our AI drug discovery market report.

Which parts of AI drug discovery are losing momentum?

AI Target Discovery has seen the clearest multi-year loss of funding weight, while AI Lead Optimization looks more like a volatile category that had an unusually busy 2025.

Target Discovery represented 19.4% of deals in 2024 and 13.2% today. Its drop in capital is much steeper, from 22.8% of reliable funding to only 1.4%.

Current Target Discovery funding totals about $47 million, compared with $188.9 million over the equivalent 2024 period.

Lead Optimization has a different story. Five deals appeared last year and just one currently. With samples that small, we would be cautious about calling that a structural retreat. The 2025 burst may simply have been unusually active.

Preclinical Prediction AI is more interesting. Deal count has risen from two in 2024 to four last year and five now, while its current median financing has fallen to $4.8 million from $31 million last year.

So the weakness is not uniform. Target Discovery has lost relative weight in both deals and capital. Preclinical Prediction is attracting more financings but smaller ones. Lead Optimization is still too lumpy to read confidently.

Are AI drug discovery startups getting older before investors fund them?

No. AI drug discovery companies receiving funding remain surprisingly young even as investors push much more money into later-stage rounds.

Median company age at financing is about three years today, compared with 3.5 years last year and three years in 2024.

Current median age rises logically with stage: roughly two years for Seed, four for Series A and five for Series B. What is unusual is how quickly some companies are reaching those later rounds.

Chai was founded in 2024 and is already at Series C. Aureka was founded in 2023 and raised a $100 million Series B this year. Syneron, founded in 2022, has reached a $150 million Series B.

The funding market is maturing much faster than the underlying companies are aging.

Young businesses are moving rapidly into financing stages and capital requirements that biotech companies traditionally reached only after much longer development cycles.

Is AI drug discovery funding shifting from the US to Asia and Europe?

AI drug discovery funding is becoming more geographically diverse, and the clearest change right now is the steady rise in Asia-Pacific deal activity.

North America still has the largest number of current financings at 17, but its share has declined from 61.3% in 2024 to 44.7% today.

Asia-Pacific went from one deal in 2024 to five last year and nine now. Its current share has reached 23.7%, making this one of the strongest multi-year changes in deal breadth anywhere in the dataset.

China is contributing meaningful transactions, including Syneron Bio's $150 million Series B and AIPher's roughly $14.9 million seed financing.

Europe requires more care. European companies currently account for 28.9% of deals but 65.2% of capital. Isomorphic's UK-based $2.1 billion round explains most of that apparent dominance.

One huge transaction can make a region look much stronger than its deal activity really is. APAC's rising deal count is the geographic shift we find more convincing because it has progressed across three consecutive periods. Who drives a region's rise, and how they stack up, is shown on the maps and grids in our market report about AI drug discovery.

Are pharma companies suddenly taking over AI drug discovery investing?

Pharma companies are showing up around bigger AI drug discovery rounds, but they are nowhere close to taking over the market.

Strategic investors participate in 26.3% of current deals, up from 21.6% last year but still well below the 38.7% we recorded in 2024.

Where the change becomes more interesting is deal size. The median current financing involving a strategic investor is roughly $51.5 million, compared with $23.45 million last year.

Syneron Bio is a good example. AstraZeneca entered a strategic collaboration with the company before continuing to support it as an investor. The partnership gives AstraZeneca access to Syneron's macrocyclic-peptide platform, while the subsequent Series B finances further platform development and clinical progression.

Earendil Labs also announced a much broader relationship with Sanofi around its AI-driven biologics platform and pipeline. Its $787 million financing disclosure cannot be treated as one clean round because the company explicitly said the money was raised across financing rounds, but the corporate involvement remains relevant.

Boltz offers another current example from the platform side. The company launched with a Pfizer relationship and has since announced a collaboration with GSK to deploy biomolecular AI models and tools across GSK's discovery work.

The trend is more about where strategic investors appear than how often they appear. They are increasingly visible around companies that can already connect AI models with real pharmaceutical discovery programs.

Why are investors willing to write billion-dollar checks for AI drug discovery now?

The biggest AI drug discovery checks are going to companies that can increasingly show a path from AI models to real molecules, pharma partnerships and clinical pipelines.

A few years ago, much of the investment case rested on whether modern AI could meaningfully improve molecular prediction and design. That technical question has not disappeared, but the leading companies now have more concrete things to show investors.

Isomorphic says its new capital will support global scaling of its drug-design engine and move therapeutic programs toward the clinic. Chai has been building commercial relationships across several major pharmaceutical companies. Syneron combines an AI-enabled discovery platform with a growing drug pipeline and an established AstraZeneca relationship.

We can see the same shift at smaller companies. Tamarind Bio says its molecular-AI infrastructure is already used across major pharma, biotech and academic organizations. Turbine is pairing virtual-cell models with proprietary experimental data and pharma collaborations. Boltz has moved quickly from widely used open models into enterprise drug-discovery deployments.

That gives late-stage investors a much broader set of things to underwrite: customer use, strategic partnerships, proprietary data, drug candidates and clinical plans alongside the quality of the AI itself.

We still do not know how many AI-designed medicines will ultimately survive clinical development. That remains the hardest test for the sector. But investors today have considerably more operating and commercial evidence to work with than they had during the first wave of AI drug discovery funding.

Has AI drug discovery already raised more in 2026 than in previous full years?

Yes. AI drug discovery has already raised more reliable capital this year than during all of 2025, even though far fewer financings have taken place so far.

Current funding equals roughly 152% of the audited 2025 full-year total. At the same time, only 38 deals have occurred so far compared with 57 during all of last year. Totals are only part of the picture, so our size estimate is built from the ground up in our report covering the AI drug discovery market.

Compared with the full 2024 calendar year, current capital is around 2.6 times higher while deal count has reached roughly 78% of that year's total.

We would not turn those figures into an annualized forecast. Private funding arrives irregularly, and a $2.1 billion transaction makes any simple run-rate calculation especially weak.

The useful conclusion is already visible without forecasting the rest of the year: investors have deployed more money than during either of the previous complete years, while financing frequency remains well below those full-year totals.

Capital per successful company is the exceptional part of this cycle.

Is AI drug discovery turning into a winner-takes-most market?

AI drug discovery increasingly looks like a winner-takes-most funding market once companies reach the stage where very large checks become possible.

Plenty of startups still raise seed and smaller venture rounds. We count 36 funded companies this year, so access to capital has certainly not collapsed around a tiny handful of names.

The distribution of dollars looks very different. A few companies now absorb most of the market's capital, and follow-on investors appear increasingly willing to fund them at a scale that was rare even one or two years ago.

De Novo Design gives us the cleanest example. Its share of total deals has been remarkably stable, while its share of funding has climbed dramatically. Investors are selecting from a familiar pool of companies and putting much more money behind the ones that appear to be pulling ahead.

The selection criteria also look tougher. Having an interesting model is becoming less distinctive on its own. The companies attracting the largest rounds increasingly combine strong AI with proprietary experimental systems, pharma relationships, valuable datasets, drug candidates or credible clinical-development plans.

For founders, that creates two very different realities. Early financing remains available across a fairly broad startup base, while the truly massive rounds are concentrating around a much smaller group of companies that can show progress beyond the model itself.

What is actually changing in AI drug discovery funding?

AI drug discovery funding is getting much deeper for a small group of companies, while the wider startup market is improving only modestly.

The biggest change is the size of the bets. Total capital has surged while deal count has barely moved year on year. Large follow-on rounds, especially at Series B and beyond, explain most of that gap.

Investor attention is also becoming more selective. New-company financings have declined as a share of the market, while existing companies absorb the overwhelming majority of capital.

De Novo Design is where this concentration is most visible. Its deal share has hardly changed, yet it now receives almost nine dollars out of every ten invested in the market.

Below the megadeals, conditions look better than last year without looking extraordinary. Typical rounds are somewhat larger and the smallest financing bucket has shrunk, but adjusted funding is still close to where it was two years ago.

Geographically, Asia-Pacific is the clearest source of new breadth. Its deal count has climbed consistently across all three periods, whereas Europe's huge capital share currently depends heavily on one UK transaction.

The most important development is what companies now need to show to unlock serious money. AI models are increasingly being judged alongside pharmaceutical partnerships, proprietary experimental loops, pipeline development and progress toward the clinic. That is pushing the strongest companies into much more capital-intensive territory.

For now, the market looks healthier and richer than it did last year, but the headline boom overstates how widely that improvement is being felt. The current cycle is rewarding a relatively small group of fast-maturing AI drug discovery platforms with amounts of capital that would have looked exceptional even recently.